Verrica Pharmaceuticals Inc. has announced new equity compensation grants for its senior management. On December 23, 2025, the Compensation Committee approved the grant of options to purchase 512,269 shares of common stock to President and CEO Jayson Rieger, with an exercise price of $8.21 per share, matching the closing price on the grant date. The Committee also approved a grant of 10,000 fully vested restricted stock units to Interim Chief Financial Officer John Kirby. These grants were made under the company's 2018 Equity Incentive Plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-335824), on December 30, 2025, and is solely responsible for the information contained therein.